Center for Cancer Biology Research

癌症生物学研究中心

基本信息

批准号：
8898842
负责人：
W KEITH MISKIMINS
金额：
$ 217.49万
依托单位：
SANFORD RESEARCH/USD
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-02 至 2016-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8898842
关键词：
Animal Model Antibodies Applications Grants Autoantibodies B lymphoid malignancy Basic Science Biological Models Biology Cancer Biology Cellular biology Centers of Research Excellence Clinical Clinical Research Complement Comprehensive Cancer Center Core Facility Data Detection Development Diagnostic tests Differentiation Antigens Doctor of Philosophy Drug Delivery Systems Faculty Flow Cytometry Foundations Funding Future Goals Grant Head and Neck Squamous Cell Carcinoma Human Image Immune response Immunology Immunotherapy Individual Institution International Journals Laboratories Malignant Neoplasms Malignant neoplasm of pancreas Malignant neoplasm of prostate Manuscripts Mediating Medical Students Membrane Mentors Methods Molecular Biology Monoclonal Antibodies Pathway interactions Patients Pilot Projects Postdoctoral Fellow Preparation Protein Kinase Proteins Publishing Radioimmunotherapy Recruitment Activity Request for Proposals Research Research Design Research Infrastructure Research Personnel Research Project Grants Research Support Research Training Role Scientist Series Serum Services Signal Transduction South Dakota Students Surface Antigens Technology Testing Training Training Programs Translational Research Tumor Biology United States National Institutes of Health Work anticancer research cancer cell career career development cytotoxic experience graduate student improved meetings molecular pathology mouse model multidisciplinary nanoparticle novel novel diagnostics programs prostate cancer cell tumor tumor progression undergraduate student

项目摘要

This is a proposal to establish a Center of Biomedical Research Excellence (COBRE) focusing on Cancer Biology with emphasis on the identification, functional characterization, and targeting of tumor specific markers and antigens. Our center will use cell and molecular biology, immunology, nanoparticle technology, and animal models to examine the development, detection, and treatment of human cancer. Five research projects are included. The goals of Project 1 (Meena Jaggi, PhD) are to understand the effects of protein kinase Dl on (3- catenin-mediated signaling and to determine if PKD1 expression influences tumor progression through this pathway. For Project 2 (Kristi Egland, PhD) a large number of membrane and secreted proteins that are expressed at elevated levels in prostate cancer cells were identified. This information will be used to develop a new diagnostic test for prostate cancer that detects autoantibodies in patient serum. Project 3 (Satoshi Nagata, PhD) will develop a panel of monoclonal antibodies to surface antigens that are highly expressed in B cell malignancies. These antibodies will be tested for their potential use in immunotherapies. Project 4 (Subhash Chauhan, PhD) will develop novel methods of treatment and drug delivery for pancreatic cancer. The goal will be to combine radioimmunotherapy and nanoparticle technology for highly specific delivery of cytotoxic compounds. Project 5 (William Spanos, MD) will focus on the role of the immune response in tumor clearance following treatment of head and neck squamous cell carcinoma. A strong mentoring plan will take advantage of the experience of an outstanding group of senior faculty with active research programs. Mentors will provide guidance for research design, manuscript preparation, grant applications, and other crucial aspects of career development. An EAC consisting of five internationally recognized scientists with broad experience in basic, translational, and clinical research has been assembled. Research capabilities will be supported by core facilities in Molecular Pathology, Flow Cytometry, Tumor Biology, and Imaging. We will recruit 3 high quality junior investigators and 1 established investigator. We will train students and post-doctoral fellows, support a seminar series, and fund pilot research projects in the field of cancer research.

这是建立卓越生物医学研究中心（COBRE）的一项建议，重点是癌症生物学，重点是鉴定，功能表征和靶向肿瘤特异性标记和抗原。我们的中心将使用细胞和分子生物学，免疫学，纳米颗粒技术和动物模型来检查人类癌症的发育，检测和治疗。包括五个研究项目。项目1（Meena Jaggi，PhD）的目标是了解蛋白激酶DL对（3-链氨蛋白介导的信号传导的影响，并确定PKD1表达是否会影响通过该途径的肿瘤进行。对于Project 2（Kristi Egland，PhD，PhD，PhD），大量的膜和分泌的蛋白质在较高的蛋白质中逐渐识别出较高的蛋白质，以鉴定出较高的细胞，以至于将其用于较高的细胞，以至于将其定为诊断。在患者血清中检测自身抗体的前列腺癌（Satoshi Nagata，PhD）将开发一组对B细胞恶性肿瘤的表面抗原的单克隆抗体。胰腺癌将是将放射性疗法和纳米颗粒技术结合起来，用于高度特异性的细胞毒性化合物（MD William Spanos）。强大的指导计划将利用主动研究计划的一群杰出的高级教师的经验。导师将为研究设计，手稿准备，赠款应用以及职业发展的其他关键方面提供指导。由五位国际认可的科学家组成的EAC已组成，具有广泛的基础，转化和临床研究经验。研究能力将由分子病理学，流式细胞仪，肿瘤生物学和成像方面的核心设施支持。我们将招募3名高质量的初级调查员和1名既定研究者。我们将培训学生和博士后研究员，支持研讨会系列，并在癌症研究领域进行基金试点研究项目。